Burning Rock Biotech Ltd
NASDAQ:BNR

Watchlist Manager
Burning Rock Biotech Ltd Logo
Burning Rock Biotech Ltd
NASDAQ:BNR
Watchlist
Price: 5.5 USD 1.05% Market Closed
Market Cap: 56.4m USD
Have any thoughts about
Burning Rock Biotech Ltd?
Write Note

Burning Rock Biotech Ltd
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Burning Rock Biotech Ltd
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
Burning Rock Biotech Ltd
NASDAQ:BNR
Gross Profit
ÂĄ363.2m
CAGR 3-Years
5%
CAGR 5-Years
22%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Gross Profit
ÂĄ14.7B
CAGR 3-Years
108%
CAGR 5-Years
67%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Gross Profit
ÂĄ6.1B
CAGR 3-Years
12%
CAGR 5-Years
82%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Gross Profit
ÂĄ4.5B
CAGR 3-Years
34%
CAGR 5-Years
45%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Gross Profit
ÂĄ9.2B
CAGR 3-Years
-11%
CAGR 5-Years
18%
CAGR 10-Years
34%
Imeik Technology Development Co Ltd
SZSE:300896
Gross Profit
ÂĄ2.7B
CAGR 3-Years
61%
CAGR 5-Years
57%
CAGR 10-Years
N/A
No Stocks Found

Burning Rock Biotech Ltd
Glance View

Market Cap
56.4m USD
Industry
Biotechnology

Burning Rock Biotech Ltd. engages in the investment of medical fields. The company is headquartered in Guangzhou, Guangdong. The company went IPO on 2020-06-12. The firm operates three segments. Central Laboratory Business segment is engaged in the sales of cancer therapy selection test to individual patients. In-Hospital Business segment is engaged in the sales of reagent kits and the provision of the facilitation services for the sale of laboratory equipment to hospitals. Pharma Research and Development Services segment provide services to companies primarily in relation to the development of targeted therapies and immunotherapies for various types of cancer, and to hospitals for their studies on cancer diagnosis and treatment. Its products include OncoScreen Plus and LungPlasma. Its NGS-based cancer therapy selection tests applicable to a broad range of cancer types, including lung cancer, prostate cancer, breast cancer and others. The firm mainly conducts its businesses in the China market.

BNR Intrinsic Value
17.37 USD
Undervaluation 68%
Intrinsic Value
Price

See Also

What is Burning Rock Biotech Ltd's Gross Profit?
Gross Profit
363.2m CNY

Based on the financial report for Dec 31, 2023, Burning Rock Biotech Ltd's Gross Profit amounts to 363.2m CNY.

What is Burning Rock Biotech Ltd's Gross Profit growth rate?
Gross Profit CAGR 5Y
22%

Over the last year, the Gross Profit growth was -4%. The average annual Gross Profit growth rates for Burning Rock Biotech Ltd have been 5% over the past three years , 22% over the past five years .

Back to Top